paliperidone · Janssen Pharms · NDA 021999
Invega
Earliest generic entry, as listed · earliest of 3 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- Generic approved · ANDA 203279, Apotex · 021999-001Approved 26 Jan 2026Detected 25 Oct 2026Historical import
- Generic approved · ANDA 205402, Pharmazone · 021999-001Approved 7 May 2026Detected 25 Oct 2026Historical import
Products covered · 5
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 021999 · 001 · RLD | tablet, extended release, oral | 3MG | open |
| 021999 · 002 · RLD | tablet, extended release, oral | 6MG | open |
| 021999 · 003 · RLD | tablet, extended release, oral | 9MG | open |
| 021999 · 004 · RLD · discontinued | tablet, extended release, oral | 12MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
| 021999 · 006 · RLD · discontinued | tablet, extended release, oral | 1.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |